Conditions
Condition-specific guides on CBD for autoimmune and inflammatory conditions. We follow the evidence wherever it leads — including when it leads to "not enough data to draw conclusions."
Each guide maps the ECS mechanism, cites the available human and animal research, and is honest about evidence gaps. Drug interactions for any medications you're already taking are covered in the drug interactions hub.
Rheumatoid arthritis
ICD-10 M05
The mechanism map, honest evidence picture, and drug-interaction realities for RA and chronic inflammatory joint pain. Written by Ron — living with RA for 30+ years.
Hashimoto's thyroiditis
ICD-10 E06.3
Educational framing only — no clinical trials for Hashimoto's + CBD. ECS-immune mechanism context, thyroid safety signal, levothyroxine timing, and what patients actually use CBD for.
Lupus (SLE)
ICD-10 M32
No clinical trials for SLE + CBD. Hutchings 2023 (n=220) found lupus patients use cannabis primarily for pain and fatigue. Medication table covers plaquenil, prednisone, mycophenolate, belimumab, and azathioprine.
Knee osteoarthritis
ICD-10 M17
Strongest human RCT evidence for CBD in joint pain. Pramhas 2023 (n=86): high-dose oral CBD added to paracetamol reduced moderate-to-severe knee pain. Topical vs oral framing; NSAIDs, celecoxib, meloxicam, and duloxetine interaction table.
Fibromyalgia
ICD-10 M79.7
Boehnke 2022 (n=878 survey): fibromyalgia patients reported perceived improvement in pain, sleep, and fatigue with CBD. No CBD-specific RCT — cannabis (THC+CBD) trials show stronger signal. Central sensitization mechanism, TRPV1 and serotonergic context. Medication table: duloxetine, pregabalin, SSRIs, tricyclics, tramadol.
Psoriatic arthritis
ICD-10 L40.5
Vela 2022 (n=68 RCT) tested CBD specifically in PsA and found no statistically significant benefit vs placebo — the most important honest disclosure for this condition. Preclinical CB2 and NF-κB mechanism context. Medication table: methotrexate, biologics, JAK inhibitors, NSAIDs, prednisone.
Ankylosing spondylitis
ICD-10 M45
No AS-specific CBD trial exists. Fitzcharles 2016 survey found AS patients use cannabis for pain and stiffness. AS is driven by the HLA-B27/IL-17/IL-23 axis — preclinical CB2 and Th17 mechanism context applies; topical CBD is not relevant for axial spine/SI joint pain. Medication table: NSAIDs, biologics (TNF + IL-17), JAK inhibitors, sulfasalazine.
Hip osteoarthritis
ICD-10 M16
Pramhas 2023 (n=86 RCT) was knee-specific — extrapolation to hip is plausible but not validated. Vela 2022 null trial cited honestly. Key distinction: hip is a deep joint; topical CBD cannot reach it. Oral CBD is the only plausible route. Medication table: acetaminophen, NSAIDs, celecoxib, meloxicam, duloxetine, tramadol.
More conditions coming
Gout, ankylosing spondylitis peripheral subtype, and sleep-specific conditions are in the research queue. Each takes time to do properly — we won't publish without primary citations.